PDUFA III Deal Includes Risk Management Fees In “Peri-Approval” Phase
This article was originally published in The Tan Sheet
The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years
You may also be interested in...
White House interest in Cornell ophthalmologist Calvin Roberts, MD, indicates that the search for a permanent FDA commissioner is continuing
The PDUFA III agreement between FDA and industry includes a provision that would allow sponsors to request the participation of outside consultants in protocol design meetings
Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures